ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Aisha T. Langford, PhD, MPH

Aisha T. Langford, PhD, MPH

Aisha T. Langford, PhD, MPH, is a freelance writer, speaker and academic researcher. She holds an appointment with the NYU School of Medicine as an assistant professor. Her research focuses on how health communication can improve individual medical decision making and reduce population health disparities in the context of clinical trial participation and chronic disease prevention. Dr. Langford holds a BA in English from the University of Virginia, an MPH in behavioral science and epidemiology from Saint Louis University School of Public Health, and a Ph.D. in health behavior and health education from the University of Michigan School of Public Health. 

Posts by Author

(©DiegoCervo/Shutterstock.com)

Tailored medication should be considered beyond conception to stabilize low disease activity and prevent flares during pregnancy, study reports.

(©Zerbor/Shutterstock.com)

Physicians should weigh the risks and benefits of adalimumab discontinuation in rheumatoid arthritis patients who achieve low disease activity, researchers report.

JIA (©PuwadolJaturawutthichai/Shutterstock.com)

Researchers from the Netherlands compare three treatment options for patients with recent onset, non-systemic juvenile idiopathic arthritis.

(©AlilaMedicalMedia/Shutterstock.com)

Two new studies find that abatacept plus prednisone improves duration of remission for giant cell arteritis patients, but not for Takayasu’s arteritis patients.

©BillionPhotos/Shuttersstock.com

Rheumatoid arthritis patients treated with mavrilimumab had significantly reduced disease activity and greater ARC20 response compared to placebo in phase IIB study.

©Arthritis Hriana/Shutterstock.com

Two doses of sirukumab, compared with placebo, improves the signs and symptoms of patients with active rheumatoid arthritis, researchers report.

(©RSzatkowski/Shutterstock.com)

A new study finds that vitamin D supplementation is associated with lower rates of acute respiratory tract infections, especially in people who are vitamin D deficient.

Baricitinib janus kinase inhibitor drug molecule. (Molekuul_be/Shutterstock.com)

Compared to placebo and adalimumab, the addition of once-daily oral baricitinib produced significant clinical improvements in RA patients, research shows.

(Combination medications  ©piotr_pabijan/Shutterstock.com)

Rheumatoid arthritis patients who fail previous methotrexate therapy respond better to TNFi–methotrexate combo, compared to a specific triple therapy, researchers say.

(Vaccinese ©adamgregor/Shutterstock.com)

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) does not prevent pneumonia in rheumatoid arthritis patients, a new study finds.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.